JAZZ News and Press, Jazz Pharmaceuticals plc From 02/03/21

Shares of GW Pharmaceuticals (NASDAQ: GWPH) were skyrocketing 46.3% as of 10:45 a.m. EST on Wednesday. The huge gain came after Jazz Pharmaceuticals (NASDAQ: JAZZ) announced plans to acquire GW for $7.2 billion. It's certainly not surprising in the least that GW Pharmace...

Jazz Pharmaceuticals (JAZZ) has been talking to GW Pharmaceuticals (GWPH) for "a bit" of time before deal announced today, CNBC's David Faber said."They've looked at this deal for quite some time is my understanding, been talking for a bit," Faber said. "Unclear whether there was any sor...

Zogenix (ZGNX) climbing 18% in premarket trading on a positive read through from Jazz Pharmaceuticals'  (JAZZ) $7.2b planned purchase of GW Pharmaceuticals (GWPH).The deal values GWPH at 9.4x EV/consensus 2021 estimated sales and if one applies a similar multiple for Zogenix it gets to a...

Moleculin Biotech (MBRX) -21% on launch of public offering.NTN Buzztime (NTN) -16%.PEDEVCO (PED) -13% after pricing stock offering.Ocugen (OCGN) -14%.Voyager Therapeutics (VYGR) -13% on termination of Parkinson’s collaboration with Neurocrine Bio.Titan Med...

Jazz Pharmaceuticals (JAZZ) is trading ~5.3% lower in the premarket after announcing that it has agreed to acquire GW Pharmaceuticals plc (GWPH) for $220.00 per American Depositary Share.The transaction in the form of $200.00 in cash and $20.00 in Jazz ordinary shares repr...

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a pote...

Jazz Pharmaceuticals (JAZZ) is trading lower today as Morgan Stanley downgrades the stock to equal-weight from overweight, citing a balanced risk-reward ahead of a key data readout from a competitor.The analyst David Risinger and the team have lowered the price target to $166 from $177, imply...

Jazz Pharmaceuticals (JAZZ) appears to be starting to clear away a legal overhang with Xyrem lawsuits, according to Evercore ISI.There are a number of class action lawsuits on Xyrem that could fasten the generic entry to as early as 2023 from 2026, according to Evercore analyst Umer Raffat.Ev...

Speaking at J.P. Morgan Annual Health Care Conference, Bruce C. Cozadd, Co-Founder, Chairman & CEO of Jazz Pharmaceuticals (JAZZ) said, the company expects to record ~$2.32 – 2.38B of revenue for 2020, unchanged from the previous guidance.With an estimated growth of ~7.3 ...

Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at...